Heart Disease

disparity, Disparities

KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.

In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients. This change potentially…

The FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese – a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from covering drugs used for obesity. This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.

In January 2021, the number of deaths from COVID-19 increased so rapidly that it has clearly become the number one cause of death in the U.S., with an average of more than 3,000 people per day dying of COVID-19 in the U.S. as of Jan. 26. Learn more in this Chart of the Week from the Peterson-KFF Health System Tracker.

In his latest column for The Wall Street Journal’s Think Tank, Drew Altman explains how a recent Bureau of Economic Analysis report makes the nation’s health care spending more tangible by breaking it down by disease. All previous columns by Drew Altman are available online.

In this column for The Wall Street Journal’s Think Tank, Drew Altman explains how a recent Bureau of Economic Analysis report makes the nation’s health care spending more tangible by breaking it down by disease.